Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior targeted conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells.  The Company's targeted Antibody Radio-Conjugates (ARCs), combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes.  Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies.